Description

Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? This book opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

Key Features

* Co-written by Graham Lees and Tamas Bartfai who has been involved in the development of drugs taken by more that 20 million people every day * Opens the windows and doors of the most regulated industry in the world, the pharmaceutical industry * Tells the story of drug development by using real examples based on current research and events * Provides an objective, lucid account of the successes and failures, shortcomings and constraints of the pharmaceutical and biotech industries * Gives insights into the development of new drugs to combat multiple conditions including cancer and pain * Balanced, unbiased account of how better to translate basic science into drug discovery

Readership

Academics/Scientists interested in working with biotech and pharma companies

Table of Contents

Proposed Contents: 1. The Art of Putting a Molecule Into Man 2. Raising & Rising Expectations 3. History is good to know 4. The "Better Betablocker Barrier" 5. Why Some Good Drugs Do Not Get a Chance & Why 6. About the Economics of Target and Clinical Candidate Selection 7. Target Based Drug Discovery: Part I 8. Changes Need to be Made 9. Target Based Drug Discovery, Part II 10. "Drugable" Targets 11. So Many Drugs, So Few Entities 12. How to Find a Candidate 13. Practicalities: The Hoops & Hurdles of Big Pharma 14. Practical Trials for a Balanced Portfolio 15. How to Improve the Odds of Finding a Safe Drug that Works 16. The Tribulations of Clinical Trials 17. Linking Putative Targets to Disease States 18. More Ways to Look for Targets 19. The Business Basics 20. Adding Value in a Growth of Industry 21. What's the Most Profitable Approach? 22. Pharmacoeconomics for Biotech 23. Shrinking Value of Targets 24. Assessing Company Assets? Look in the Library 25. To Merge or Not to Merge? 26. Working with the Food & Drug Administration (FDA) 27. Regulating Regulatory Regimens Reliably 28. The Hypothesis Is: There is a Better Way 29. What are "We" all Working on? 30. More Tablets Taken per Day than Meals Served

Details

No. of pages:
328
Language:
English
Copyright:
© 2005
Published:
Imprint:
Academic Press
Print ISBN:
9780123695338
Electronic ISBN:
9780080919232

Reviews

"Doody's 3 Star Review: It was refreshing reading about these matters from a different perspective. The critical nature of the book, I would imagine, was intentional to play the proverbial "devil's advocate". This book truly caused me to rethink some attitudes and opinions I have had about pharmaceutical company behavior in the marketplace. It's nice that once in a while such a refreshing publication comes along." - Albert Wertheimer, B.S., MBA, PhD, Temple University School of Pharmacy for DOODY'S "[This book] is very readable and insightful. I am hopeful that many people will pick it up, and develop a better appreciation for what goes into making the treatments that everyone wants!" - Dennis W. Choi, M.D., Sr. VP Merck (2006) "Anyone who thinks solutions to drug development are just around the corner would be well-advised to get this insider's views as to where the real problems lie." - Floyd Bloom, CEO Neurome, former Editor of Science magazine (2006) "...a very informative and exciting book filling an important niche. Very easy to read, it encouraged me to think about several things." - Richard Nass, Vanderbilt University (2006)